162 related articles for article (PubMed ID: 25031379)
1. A Combination of rhBMP-2 (Recombinant Human Bone Morphogenetic Protein-2) and MEK (MAP Kinase/ERK Kinase) Inhibitor PD0325901 Increases Bone Formation in a Murine Model of Neurofibromatosis Type I Pseudarthrosis.
El-Hoss J; Cheng T; Carpenter EC; Sullivan K; Deo N; Mikulec K; Little DG; Schindeler A
J Bone Joint Surg Am; 2014 Jul; 96(14):e117. PubMed ID: 25031379
[TBL] [Abstract][Full Text] [Related]
2. Improved union and bone strength in a mouse model of NF1 pseudarthrosis treated with recombinant human bone morphogenetic protein-2 and zoledronic acid.
Deo N; Cheng TL; Mikulec K; Peacock L; Little DG; Schindeler A
J Orthop Res; 2018 Mar; 36(3):930-936. PubMed ID: 28767180
[TBL] [Abstract][Full Text] [Related]
3. A murine model of neurofibromatosis type 1 tibial pseudarthrosis featuring proliferative fibrous tissue and osteoclast-like cells.
El-Hoss J; Sullivan K; Cheng T; Yu NY; Bobyn JD; Peacock L; Mikulec K; Baldock P; Alexander IE; Schindeler A; Little DG
J Bone Miner Res; 2012 Jan; 27(1):68-78. PubMed ID: 21956219
[TBL] [Abstract][Full Text] [Related]
4. Modulation of endochondral ossification by MEK inhibitors PD0325901 and AZD6244 (Selumetinib).
El-Hoss J; Kolind M; Jackson MT; Deo N; Mikulec K; McDonald MM; Little CB; Little DG; Schindeler A
Bone; 2014 Feb; 59():151-61. PubMed ID: 24269278
[TBL] [Abstract][Full Text] [Related]
5. JNK inhibitors increase osteogenesis in Nf1-deficient cells.
Sullivan K; El-Hoss J; Little DG; Schindeler A
Bone; 2011 Dec; 49(6):1311-6. PubMed ID: 21964323
[TBL] [Abstract][Full Text] [Related]
6. Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.
de la Croix Ndong J; Stevens DM; Vignaux G; Uppuganti S; Perrien DS; Yang X; Nyman JS; Harth E; Elefteriou F
J Bone Miner Res; 2015 Jan; 30(1):55-63. PubMed ID: 25043591
[TBL] [Abstract][Full Text] [Related]
7. MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors.
Jessen WJ; Miller SJ; Jousma E; Wu J; Rizvi TA; Brundage ME; Eaves D; Widemann B; Kim MO; Dombi E; Sabo J; Hardiman Dudley A; Niwa-Kawakita M; Page GP; Giovannini M; Aronow BJ; Cripe TP; Ratner N
J Clin Invest; 2013 Jan; 123(1):340-7. PubMed ID: 23221341
[TBL] [Abstract][Full Text] [Related]
8. Hyperactive Ras/MAPK signaling is critical for tibial nonunion fracture in neurofibromin-deficient mice.
Sharma R; Wu X; Rhodes SD; Chen S; He Y; Yuan J; Li J; Yang X; Li X; Jiang L; Kim ET; Stevenson DA; Viskochil D; Xu M; Yang FC
Hum Mol Genet; 2013 Dec; 22(23):4818-28. PubMed ID: 23863460
[TBL] [Abstract][Full Text] [Related]
9. Developmental dosing with a MEK inhibitor (PD0325901) rescues myopathic features of the muscle-specific but not limb-specific Nf1 knockout mouse.
Summers MA; Vasiljevski ER; Mikulec K; Peacock L; Little DG; Schindeler A
Mol Genet Metab; 2018 Apr; 123(4):518-525. PubMed ID: 29477258
[TBL] [Abstract][Full Text] [Related]
10. Distal tibial fracture repair in a neurofibromatosis type 1-deficient mouse treated with recombinant bone morphogenetic protein and a bisphosphonate.
Schindeler A; Birke O; Yu NY; Morse A; Ruys A; Baldock PA; Little DG
J Bone Joint Surg Br; 2011 Aug; 93(8):1134-9. PubMed ID: 21768643
[TBL] [Abstract][Full Text] [Related]
11. Modulation of spine fusion with BMP-2, MEK inhibitor (PD0325901), and zoledronic acid in a murine model of NF1 double inactivation.
Bobyn JD; Deo N; Little DG; Schindeler A
J Orthop Sci; 2021 Jul; 26(4):684-689. PubMed ID: 32713795
[TBL] [Abstract][Full Text] [Related]
12. Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice.
Chang T; Krisman K; Theobald EH; Xu J; Akutagawa J; Lauchle JO; Kogan S; Braun BS; Shannon K
J Clin Invest; 2013 Jan; 123(1):335-9. PubMed ID: 23221337
[TBL] [Abstract][Full Text] [Related]
13. Continuous inhibition of MAPK signaling promotes the early osteoblastic differentiation and mineralization of the extracellular matrix.
Higuchi C; Myoui A; Hashimoto N; Kuriyama K; Yoshioka K; Yoshikawa H; Itoh K
J Bone Miner Res; 2002 Oct; 17(10):1785-94. PubMed ID: 12369782
[TBL] [Abstract][Full Text] [Related]
14. rhBMP-2 and Intramedullary Fixation in Congenital Pseudarthrosis of the Tibia.
Richards BS; Anderson TD
J Pediatr Orthop; 2018 Apr; 38(4):230-238. PubMed ID: 27261960
[TBL] [Abstract][Full Text] [Related]
15. Dose- and time-dependent effects of recombinant human bone morphogenetic protein-2 on the osteogenic and adipogenic potentials of alveolar bone-derived stromal cells.
Park JC; Kim JC; Kim BK; Cho KS; Im GI; Kim BS; Kim CS
J Periodontal Res; 2012 Oct; 47(5):645-54. PubMed ID: 22471302
[TBL] [Abstract][Full Text] [Related]
16. Maximizing bone formation in posterior spine fusion using rhBMP-2 and zoledronic acid in wild type and NF1 deficient mice.
Bobyn J; Rasch A; Kathy M; Little DG; Schindeler A
J Orthop Res; 2014 Aug; 32(8):1090-4. PubMed ID: 24719295
[TBL] [Abstract][Full Text] [Related]
17. Targeting mitogen-activated protein kinase kinase with the inhibitor PD0325901 decreases hepatocellular carcinoma growth in vitro and in mouse model systems.
Hennig M; Yip-Schneider MT; Wentz S; Wu H; Hekmatyar SK; Klein P; Bansal N; Schmidt CM
Hepatology; 2010 Apr; 51(4):1218-25. PubMed ID: 20112426
[TBL] [Abstract][Full Text] [Related]
18. Modeling bone morphogenetic protein and bisphosphonate combination therapy in wild-type and Nf1 haploinsufficient mice.
Schindeler A; Ramachandran M; Godfrey C; Morse A; McDonald M; Mikulec K; Little DG
J Orthop Res; 2008 Jan; 26(1):65-74. PubMed ID: 17787010
[TBL] [Abstract][Full Text] [Related]
19. Activated MEK cooperates with Ink4a/Arf loss or Akt activation to induce gliomas in vivo.
Robinson JP; Vanbrocklin MW; Lastwika KJ; McKinney AJ; Brandner S; Holmen SL
Oncogene; 2011 Mar; 30(11):1341-50. PubMed ID: 21057530
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration.
Brown AP; Carlson TC; Loi CM; Graziano MJ
Cancer Chemother Pharmacol; 2007 Apr; 59(5):671-9. PubMed ID: 16944149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
